Dataset from An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects

The purpose of this study is to evaluate the effectiveness, tolerability, and safety of
oxymorphone immediate release (IR) oral liquid as an analgesic for acute postoperative pain
in pediatric subjects.

This post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer
promotes opioids and no longer markets Opana® ER.